Biosurface Engineering Technologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://biosetinc.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study Evaluating Amplex Compared To Autograft Bone In Foot and Ankle Fusion Surgery
Phase 1
- Conditions
- Arthritis
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- BioSurface Engineering Technologies, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01224119
- Locations
- 🇨🇦
Dr. Mark Glazebrook, Halifax, Nova Scotia, Canada
Pilot Study to Assess Safety/Prelimary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery
Phase 1
- Conditions
- Degenerative Disc DiseaseSpondylolisthesis
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- BioSurface Engineering Technologies, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00798239
- Locations
- 🇨🇦
Confidential, Montreal, Quebec, Canada
Pilot Study to Assess Safety/Preliminary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery
Phase 1
- Conditions
- Degenerative Disc DiseaseSpondylolisthesis
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- BioSurface Engineering Technologies, Inc
- Target Recruit Count
- 22
- Registration Number
- NCT00798902
- Locations
- 🇺🇸
Confidential, Tyler, Texas, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
News
No news found